$800,000.00 in Sales Expected for Immune Design Corp (IMDZ) This Quarter

Equities analysts forecast that Immune Design Corp (NASDAQ:IMDZ) will announce $800,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Immune Design’s earnings, with the lowest sales estimate coming in at $570,000.00 and the highest estimate coming in at $1.03 million. Immune Design reported sales of $490,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 63.3%. The business is expected to announce its next earnings report on Wednesday, March 20th.

On average, analysts expect that Immune Design will report full year sales of $3.20 million for the current financial year, with estimates ranging from $1.70 million to $6.00 million. For the next financial year, analysts anticipate that the business will report sales of $6.88 million, with estimates ranging from $2.20 million to $16.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Immune Design.

Several research analysts have recently weighed in on the company. Zacks Investment Research raised Immune Design from a “sell” rating to a “hold” rating in a research note on Monday. Royal Bank of Canada downgraded Immune Design from an “outperform” rating to a “sector perform” rating and reduced their target price for the stock from $9.00 to $6.00 in a research note on Friday, February 22nd. HC Wainwright downgraded Immune Design from a “buy” rating to a “neutral” rating in a research note on Thursday, February 21st. Finally, ValuEngine raised Immune Design from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Five analysts have rated the stock with a hold rating, The stock has an average rating of “Hold” and an average price target of $5.17.



Immune Design stock traded down $0.02 during mid-day trading on Wednesday, hitting $5.83. The company had a trading volume of 565,208 shares, compared to its average volume of 1,113,967. Immune Design has a 12-month low of $1.10 and a 12-month high of $5.85. The firm has a market cap of $282.96 million, a PE ratio of -3.33 and a beta of 3.49.

Several hedge funds have recently made changes to their positions in the company. Svennilson Peter acquired a new position in shares of Immune Design during the 4th quarter worth approximately $8,636,000. BlackRock Inc. raised its stake in shares of Immune Design by 1.9% during the 4th quarter. BlackRock Inc. now owns 2,132,748 shares of the biotechnology company’s stock worth $2,773,000 after buying an additional 39,581 shares during the period. Vanguard Group Inc raised its stake in shares of Immune Design by 0.7% during the 3rd quarter. Vanguard Group Inc now owns 1,615,442 shares of the biotechnology company’s stock worth $5,574,000 after buying an additional 11,006 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Immune Design by 48.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 661,961 shares of the biotechnology company’s stock worth $2,284,000 after buying an additional 214,935 shares during the period. Finally, Two Sigma Investments LP raised its stake in shares of Immune Design by 194.7% during the 4th quarter. Two Sigma Investments LP now owns 415,254 shares of the biotechnology company’s stock worth $540,000 after buying an additional 274,335 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

Immune Design Company Profile

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Featured Story: What are Institutional Investors?

Get a free copy of the Zacks research report on Immune Design (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.